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ABSTRACT 
 
Investigating Potential Bioactive Compounds from Rhodococcus and Their Effects on MCF7 
Breast Cancer Cells 
by 
Megan Crabtree 
 
Many drugs used in the treatment of various cancers are derived from or influenced by 
compounds from nature. The soil bacterium Rhodococcus is of interest because of its identified 
secondary metabolic pathways and the production of novel natural antibiotics from several 
strains.  In this study a solid agar extraction method was used to collect compounds from 
strains of Rhodococcus. These bacterial compound extracts were then tested using a MTT assay 
in order to evaluate their effectiveness in augmenting MCF7 breast cancer cell death. The 
results of two way ANOVA analyses revealed 18 compound extracts from 15 strains of 
Rhodococcus that showed significant p-values when assayed with MCF7 breast cancer cells but 
nonsignificant interaction p-values when assayed with the healthy cell control. These results 
prompt further identification of specific compounds present in the bacterial extract that caused 
cell death as well as a mechanism of interaction with the breast cancer cells.     
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CHAPTER 1 
INTRODUCTION 
Cancer at a Glance 
In recent years cancer has ranked number 2 among the leading causes of death in the 
United States. It is estimated that in 2012 alone there were 577,000 deaths from this disease 
along with 1.6 million new cases of cancer diagnosed in the United States. The occurrence of 
this disease in both men and women across the racial divides makes it a cause for concern in 
the global community. Improvements in cancer treatments across the spectrum of cancers have 
aided in increasing the 5-year survival rate from 49% to 67% over a 30-year period (American 
Cancer Society, 2012). Improvements in cancer treatments not only stem from a more in-depth 
understanding of cancer cell behavior at the cellular level and organismal level but also from 
improved treatment technologies. 
Today breast cancer is the most frequently diagnosed cancer among women and ranks 
second in the leading cause of cancer death in this gender (American Cancer Society, 2012). 
Depending on factors such as cancer cell characteristics, size, stage, and patient preference, the 
current treatments for breast cancer include lumpectomy, mastectomy, hormone therapy, and 
a combination of radiation and chemotherapy drugs. These treatments have increased the 10- 
year survival rate of breast cancer patients to 83% (American Cancer Society, 2012). While it 
has been demonstrated that the current treatment plans that involve chemotherapy drugs are 
effective, these chemicals are often physically taxing to the patient and damaging to the 
healthy tissues of the body. The compounds that have emerged from nature have been shown 
to be successful in the treatment of many diseases and conditions without all of the side effects 
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that are associated with traditional pharmaceuticals. A more in depth look into compounds 
isolated from nature could be the key to more specific and successful treatment of cancer that 
is less taxing to the body.  
History of Cancer Treatment 
 Many drugs used today to treat a wide variety of human diseases and conditions are 
derived from compounds that have been isolated from nature. In the past 20 years there have 
been great strides seen in the area of biotechnology. This has given scientists the ability to 
synthesize compounds. This opportunity has shifted the focus from isolating natural products to 
creating synthetic compounds in hopes of designing more efficient drugs. This shift brought 
great hope and possibilities in the beginning stages of its exploration; however, there has not 
been the large increase in drug productivity that was first hoped.  
A 25-year study investigated the trend in the production of new active substances 
(NASs), also referred to as New Chemical Entities (NCEs). Initially there was a sharp increase in 
the number of synthesized drugs that had been approved for clinical testing. As time 
progressed it was seen that the number of synthesized drugs approved for clinical trials had 
decreased by a large margin (Newman and Cragg 2007). This same 25-year study evaluated all 
the drugs used for the treatment of all diseases in every country from every source. It was 
found that only 30% could be classified as purely synthetic in origin.   The other 70% of the 
drugs examined where either a natural product or had some basis in a natural product such as a 
natural mimic, nature derived pharmacophore, or natural product with a synthetic modification 
(Newman and Cragg 2007). With all of the advancements in synthesis technology as well as a 
11 
 
better understanding on how chemical entities impact the cell under disease conditions, a large 
number of successful chemical products still have a natural basis. In this same study by 
Newman and Cragg, a closer look was given to those drugs on the market that are specifically 
anticancer. Out of the 175 drugs in this category that are available to Japan and the Western 
World, only 24% can be classified as purely synthetic. The other 76% of the anticancer drugs are 
natural products or have some natural product influence (Newman and Cragg 2007).  These 
percentages demonstrate the vast influence that nature has on providing effective compounds 
to help treat a wide range of diseases and has led many scientists to reconsider the exploration 
of natural products (Zhu et al. 2011).   
  
Natural Compounds Inhibiting the mTOR Pathway 
 Depending on the cancer cell type and stage of progression, cancerous cells can present 
one or multiple types of mutations. These mutations can occur in regulatory pathways and lead 
to uncontrolled proliferation, angiogenesis, and evasion of cell death, which is a modification of 
the cellular response that promotes cell survival instead of cell death when the cell receives 
stress stimuli. Recently scientists have explored the use of kinase inhibitors to correct or bypass 
the mutations in regulatory pathways. Kinases are enzymes responsible for adding a phosphate 
group to another protein. This can cause the phosphorylated protein to undergo a 
conformational change. This conformational change can result in activation of an enzyme or 
series of enzymes within a pathway that promote essential cell processes such as metabolism, 
protein synthesis, and proliferation.  
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 An important regulator within the cell is mTOR, a serine/threonine kinase. This protein 
is responsible for regulating cell functions such as cell growth, transcription, translation, 
metabolism, energy balance, and cell survival. It works by acting on signals carrying information 
such as nutrient levels, hormones, various growth factors, and other cell stresses and activating 
or inhibiting the appropriate downstream pathways (Watanabe et al. 2011). For example, a 
receptor on the surface of the cell binds to a growth factor and activates a signaling cascade. 
This signal gets passed through a series of enzymes to mTOR. From here mTOR is responsible 
for phosphorylating transcription factors and translational regulators that promote cell growth 
and survival while at the same time inhibiting enzymes that would result in cell death.    
Given its important role in regulating cell death and cell survival, the mTOR pathway has 
been a target of some recent anticancer drugs with varying amounts of success. Sirolimus, also 
known as rapamycin is a kinase inhibitor that is derived from a soil sample collected from Ester 
Island, Rapa Nui. It was identified as a macrolide antibiotic produced by the bacterium 
Streptomyces hygroscopicus  (Vezina et al. 1975). Upon discovery and extraction using organic 
solvents, rapamycin was initially used as an antifungal against Candida albicans, Cryptococcus 
neoformans, and Aspergillus fumigatus. These fungi can cause oral and genital infections, fungal 
meningitis, and invasive lung infections in patients who have suppressed immune systems 
(Vignot et al. 2004).  Rapamycin is currently used as an immunosuppressant in patients who 
undergo organ transplantation because of its effectiveness in prohibiting T-lymphocyte 
activation and proliferation.   
Along with immunosuppressive properties, it was also discovered that rapamycin 
displayed antiproliferative characteristics. The National Institutes of Cancer (NIC) screened 60 
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tumor cell lines and found that there was rapamycin sensitivity in doses under 2000 ng/ml in 
leukemia, ovarian, breast, central nervous system, and small cell lung cancer cell lines (Vignot et 
al. 2004).  After success in clinical trials, Rapamycin was approved in 1999 by the FDA for use in 
anticancer treatment (Zhu et al. 2011). Investigations continue in creating different analogues 
of rapamycin to more specifically target different types of cancer based on their defining 
characteristics and behaviors. Two successful analogues of rapamycin currently on the market 
are Everolimus and Temsirolimus, which are both used to impede the growth and spread of 
advanced renal cell carcinoma in cases of tumor resistance to other anticancer drugs. Both of 
these drugs have been successful in extending the survival of the patient for a number of 
months to years (Zhu et al. 2011).  
In recent years scientists have taken a closer look at the effects that rapamycin has on 
breast cancer. In this study breast cancer cell lines MDA-MB-231, T47D, MCF-7, and SK-BR3 
were examined. These cell lines were selected based on different cell characteristics (Table 1). 
 
Table 1: Breast cancer cell lines and their receptor characteristics. ER-Estrogen receptor. erbB2- 
an epidermal growth factor receptor.  
Cell Line Characteristics Rapamycin Sensitivity 
MDA-MB-231 ER-Negative 
Does not overexpress erbB2 
no 
T47D 
 
ER-Positive yes 
MCF-7 
 
ER-Positive yes 
SKBR3 ER- Negative 
erbB2-overexpressing 
yes 
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It was found that the cell lines T47D, MCF-7, and SKBR3 showed sensitivity to rapamycin 
while MDA-MB-231 showed resistance (Table 1). This study gave insight into the type of cell 
profile or receptors that need to be present in order for rapamycin to be effective in halting 
cancer progression (Chang et al. 2004).  
 
The Use of Steroids in Anticancer Treatment 
Steroids are characterized by their origin and their chemical structure. They are fat 
soluble molecules that originate from a plant or animal source and have a steroid nucleus that 
contains three 6-member carbon rings and one 5-member carbon ring.  The human body has 
the ability to synthesize and secrete steroids into the bloodstream. These are referred to as 
steroid hormones and are responsible for regulating bodily functions that include the 
antiinflammatory response, sexual maturation, and fetal development during pregnancy. 
Through a multistep process called sterodogenesis, cholesterol is converted to progestins, then 
to androgens, and lastly into estrogens. The regulation of this process is essential in ensuring 
the body has a correct response to stimuli (Gupta et al. 2013).  
Some cancer cell types have been shown to be stimulated by certain steroid hormones. 
Estrogen has proven to be a major player in promoting proliferation in some hormone sensitive 
breast, uterine, ovarian, prostate, and endometrial cancers (Gupta et al. 2013). Estrogen 
receptors in breast tissue are located on the cellular membrane and in the cytoplasm. These 
receptors have 2 isoforms, ERα and ERβ. Both isoforms are ligand-regulated transcription 
factors that transmit hormone signals to cause various responses in the cell. In normal breast 
tissue, ERα and ERβ bind estradiol causing a signaling cascade that controls proliferation and 
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differentiation of the cell. These 2 isoforms are present at equally low levels in normal breast 
tissue; however, in some type of breast cancer ERα is overexpressed. This overexpression 
stimulates the hormone sensitive cells to excessively proliferate in response to estrogen (Renoir 
et al. 2013). Estrogens have a direct effect on cell proliferation in certain hormone sensitive 
cancers. This has prompted researchers to focus their treatment efforts on disrupting 
steroidogenesis with aromatase inhibitors and disrupting the ability for estrogen to bind to its 
receptors. Some successful steroid drugs on the market have a natural origin or natural 
influence. Further exploration of sources of steroid production such as Rhodococcus could 
provide even more success in this cancer treatment approach (Renoir et al. 2013).  
For their use as anticancer agents, steroids have been chemically modified to act as 
cytotoxic and cytostatic agents. The use of antiestrogens, a cytostatic approach in hormone 
sensitive breast cancer, has shown some success in arresting tumor development. 
Antiestrogens compete with endogenous estrogens for binding with estrogen receptors. When 
the antiestrogen binds to the receptor, it does not initiate the signaling cascade that eventually 
leads to cell proliferation. This prevents the estrogen sensitive breast cancer cells from dividing 
in the presence of estrogen (Gupta et al. 2013). 
 Antiestrogens became an area of interest following the initial success of tamoxifen for 
treating breast cancer. Tamoxifen emerged as a treatment in the early 1970s and still remains 
an effective choice for treating receptor positive breast cancer in women who are both 
premenopausal and postmenopausal. This synthetic drug works through a competitive inhibitor 
method where it binds in the place of estrogen and does not stimulate cellular growth. While 
this drug has proven successful, resistance is always a factor when dealing with an endocrine 
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treatment. There has been resistance to the tamoxifen in later stages of breast cancer as well 
as in breast cancers that overexpress the ErbB-2 gene, which makes up 15%-20% of all breast 
cancers diagnosed (Clemons et al. 2002). 
To combat cancer cell drug resistance further research has been conducted to 
investigate the binding pocket of the estrogen receptors. In understanding the structure of the 
receptor, a more specified competitive inhibitor can be designed. It was seen that a 
modification at position 7α or 11β is effective in promoting antiestrogenic activity. This led to 
the discovery of nine potential steroidal estrogens, all of which have shown success and 
promise in clinical trials (Table 2). 
Table 2: Modified steroids that have shown potential as an antiestrogen 
treatment in breast cancer cells that are hormone sensitive (Gupta, Kumar,  
and Negi, 2013). 
 
 
 
 
 
 
 
Fulvestrant (161), marketed under the name “Faslodex”, is currently in clinical use 
against breast cancers that are resistant to tamoxifen. To date it remains the only steroidal 
antiestrogen that down regulates ERα and does not have estrogenic activity. This means that it 
does not mimic or block the actions of naturally occurring estrogen in the body. Fulvestrtant 
works by binding to the estrogen receptors and inhibiting the receptors from dimerizing and 
becoming active transcription factors. In addition to deactivation, the binding of fulvestrant to 
1. SR16137 (153) 
2. SR16234 (154) 
3. RU3941 (155) 11β-Amidoalkoxyphenyl estradiol (159) 
4. RU51625 (156) 
5. ICI 164,384 (157) 
6. 11β-Perfluorenated fulvestrant (158) 
7. 11β-Amidoalkoxyphenyl estradiol (159) 
8. 11β-(4-Pentafluorinated alkylsulphonylpentayloxyphenyl estradiol (160) 
9. Fulvestrant (161) 
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the estrogen receptors speeds up the degradation of the estrogen receptors thus decreasing 
the number of them in the cell. In this case tumor cells that are estrogen dependent and thrive 
by using estrogen as a growth factor die off because they are not getting the excess amount of 
growth signaling that promotes cell division and growth. This competitive binding does not 
cause all of the estrogen receptors to undergo degredation, thus allowing the naturally 
occurring estrogen to function on the remaining receptors in the cell. The other promising 
steroidal antiestrogens are SR 16137 (153) and SR 16234 (154), which act as a competitive 
inhibitor similar to tamoxifen (Gupta et al. 2013).   
 
Polar Compounds as Anticancer Agents 
Histones play a large role in gene expression in the cell. Histone acetylation by histone 
acetyltransferases (HAT) cause the condensed chromatin to relax. When the DNA is relaxed, it 
provides the opportunity for the exposed genes to be transcribed. The reverse process, histone 
deacetylation by histone deacetylases (HDAC), removes the acetyl group from the histone and 
causes DNA condensation. This is a highly regulated process and disruption of HAT and HDAC is 
associated with cancer (Schmudde et al. 2010). 
It is understood that in addition to genetic mutations epi-genetic changes to the 
regulation of HAT and HDAC can alter cell phenotype. Regulation of gene expression has been 
introduced as another method of cancer treatment. HDAC inhibitors (HDIs) are molecules that 
interfere with the function of histone deacetlyase (Richon 2006; Richon et al. 2009). They work 
by binding to the catalytic domain of histone deacetlyase and preventing it from removing the 
acetyl group from the histone protein. This leaves the DNA in a relaxed state and more 
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transcriptionally active (Schmudde et al. 2010). By altering the transcription of about 22% of 
genes, HDIs have shown to be effective in causing cell cycle arrest, terminal differentiation, or 
apoptosis in transformed cells.  
After small polar molecule screens in the 1970s through 1990s, several molecules 
emmerged from screens of bishydroxamic acids that showed inhibitory potential. These 
molecules lead to the development of vorinostat (also known as suberoylanilide hydroxamic 
acid or SAHA). Vorinostat is a synthetic, second generation polar-planar compound. It is a 
potent HDI and acts by biding to the catalytic domain of the histone deacetylase. In addition 
vorinostat increases the acetylation of nonhistone related transcription factors such as p53, 
HIF-1α, and EF2 and also acetylation of cytoplasmic proteins α-tubulin, cortactin, and HSP90 
(Richon et al. 2009).  This change in acetylation pattern in the cell has been shown to induce 
differentiation, arrest cell growth, and induce apoptosis in transformed cells at a low dose that 
does not prove to be toxic to normal cells (Richon 2006). It was approved by the US Food and 
Drug Administration for the treatment of cutaneous T cell lymphoma in October 2006 (Hymes, 
2010; Schmudde et al. 2010).  
 
Nature Derived Histone Deacetylase Inhibitor 
The only other approved HDI currently on the market for treatment of T cell lymphoma 
is romidepsin (Lu et al. 2012). This drug got FDA approval in November 2009 and also goes by 
the name Istodax. Romidepsin is a cyclic peptide antibiotic that was isolated from the 
bacterium Chromobacterium violaceum. Similar to vorinostat, romidepsin inhibits histone 
deacetylase and alters gene expression in the cell. This has been shown to not only increase 
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histone acetylation but also increase p21 and cyclin E and decrease Cyclin D1, which leads to 
cell cycle arrest at both the G1 and G2/M phases (Hymes, 2010).  
Romidepsin and its success in treating T cell lymphoma has promoted further 
exploration as to its effect on other cancers. In preclinical models, romidepsin has been shown 
to induce apoptosis of lung, breast, and melanoma cancers. (Hymes, 2010). Combination 
studies with romidepsin and cisplatin have shown promise in clinical trials by causing DNA 
damage induced apoptosis in ovarian cancer (Wilson et al. 2012). This drug is also in phase II 
clinical trials with patients who have recurrent or metastatic head and neck cancer and has 
shown mild success in stopping tumor progression (Haigentz et al. 2012).   
 
Bioactive Compounds from Bacterial Families 
In an expansive phylogenetic study the origins of many successful and commonly used 
natural drug-like structures were analyzed. From this study the top 10 phylogenic families that 
have produced the highest number of drugs approved or currently in clinical trials were 
identified. The family Actinomycetales contains 9 genera that have been known to produce 
compounds with drug activity (Zhu et al. 2011).  Presently, these 9 genera have been studied 
and shown to be successful at producing drug-like compounds; however, there has been little 
focus on the other species within this family and their role in creating drug-like compounds. 
Close examination of the structure of the nature-derived approved and clinical trial drugs in use 
today reveals that they are composed of several dozen molecular scaffolds, or core structures. 
These molecular scaffolds are created by enzymes that are partly encoded in specific secondary 
metabolite gene clusters in a selected group of species. It is not known if these bioactive 
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compounds are present within select species or scattered within the phylogenetic tree; 
however, evidence from the drug productive families to date suggests that they are clustered 
(Zhu et al. 2011). Exploring species that are closely related to species that are known to 
produce useful compounds may be a good strategy of bioprospecting. This strategy may reveal 
new natural product compounds that could potentially be of great importance to the medical 
community. 
In looking at the bacterial phylogenetic tree for the order Actinomycetales, the family 
Nocardiaceae, which includes Rhodococcus, is related to the family Corynebacteriaceae.  In 
2000 the family Corynebacteriaceae was identified as a drug-producing family. Due to this 
discovery it has quickly become an focus of bioprospecting research (Zhu et al. 2011). Given the 
observation that drug producing families tend to cluster in the phylogenetic tree rather that 
scatter, the family Nocardiaceae, more specifically the genus Rhodococcus, would be a good 
area of focus in hopes of investigating potential bioactive compounds.   
The Genus Rhodococcus 
 The bacterium Rhodococcus, a genus of aerobic, gram positive bacteria, is a member of 
the order Actinomycetales. This genus displays a wide range of different phenotypes and 
inhabits many environments. It has been isolated from a variety of locations including sea level 
and Alpine soils and deep sea and coastal sediments (de Carvalho et al. 2005). This order, which 
has shown great success in producing drug-like products, includes Streptomyces, a major 
antibiotic producer widely used in medicine today (McLeod et al. 2006). Rhodococcus is best 
known for its impact on industry in the areas of fossil fuel desulfurization and the production of 
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acrylamide and acrylic acid. Rhodoccucus is also known for bioactive steroid production, which 
makes it a target for further exploration in its use in a medical setting.  
Genome Sequencing of Rhodococcus 
A better understanding of the genus Rhodococcus came to light when the genome of 
strain RHA1 was sequenced and examined (McLeod et al. 2006). RHA1 is a strain of 
Rhodococcus that has been isolated from soil and is best known for its ability to break down 
polychlorinated biphenyls (PCBs). This strain is also noted for its ability to use aromatic 
compounds for its source of carbon. The genome consists of 9,702,737 base pairs compiling 4 
linear DNAs, 1 chomosome and 3 plasmids. It has also been observed that the DNA contains a 
high percentage of guanine and cytosine content.  
Sequencing of this strain revealed that Rhodococcus has a diverse secondary 
metabolism. This discovery has led to bioactive compound discovery, thus opening the door to 
the potential of this bacterium to influence other areas of science. In examining the genome it 
was discovered that RHA1 contains 9,145 predicted protein coding sequences. Based on current 
knowledge 38.4% of these sequences encode proteins of unknown function (McLeod et al. 
2006). When the secondary metabolism of RHA1 was investigated, it was found that the 
genome encodes for 24 nonribosomal peptide synthatases and 7 polyketide synthases. Other 
Actinomycetes also possess these secondary metabolic genes, all of which are involved in cell 
signaling, pigment production, siderophores, and antibiotic production. This finding of a 
relatively large number of potential secondary metabolic genes is of interest because no 
rhodococcal secondary metabolites had been reported up to this point (McLeod et al. 2006). 
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Upon further investigation of the genome, it was discovered that RHA1 contains an opp-
encoded oligopeptide transporter, which is a known regulator of secondary metabolic genes 
(McLeod et al. 2006). These unidentified synthases and transporters show promise in 
uncovering more applications for this genus of bacteria. 
Bioactivity from Compounds Isolated from Rhodococcus 
Until the published work of McLeod, Rhodococcus was not widely investigated for the 
potential production of secondary metabolites. Shortly after the complete sequencing of the 
RHA1 genome, an in-depth look at the genome resulted in the discovery of 2 antimicrobial 
peptides from Rhodococcus josti K01-B0171. These compounds were isolated from a soil 
sample taken from Yunnan Province, China. Two cyclic peptide structures demonstrated a 
lariate or “lasso” type structure and were named lariatins A and B. Both Lariatin A and B were 
unable to inhibit the growth of Gram negative strains; however, they were both able to inhibit 
the growth of Gram positive Mycobacterium smegmatis. In addition it was found that lariatin A 
was able to inhibit the growth of Mycobacterium tuberculosis (Iwatsuki et al. 2007). 
A lab in Japan isolated and identified a new antibiotic from a strain of Rhodococcus. 
Aurachin RE that emerged from the strain R. erythropolis JCM 6824. It is a quinolone antibiotic 
that has a similar structure to aurachin C antibiotics that had previously been identified from 
Stigmatella aurantiaca. Compared to aurachin C, aurachin RE has a wider scope of antibiotic 
activity against Gram positive activity (Kitagawa and Tamura 2008). 
 Further investigation was done in a lab in Florida focusing on the potential of 
Rhodococcus. The investigation involved horizontal gene transfer and the production of 
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antibiotics by Rhodococcus. In this study Rhodococcus was cocultured with Streptomycete 
padanus, which is known to produce the antibiotic actinomycin. This coculturing resulted in the 
production of 2 antibiotics, Rhodostreptomycin A and Rhodostreptomycin B by the strain of 
Rhodococcus. These results indicate that gene transfer occurred between these 2 cocultured 
bacteria that resulted in the production of a new antibiotic (Kurosawa et al. 2008).  
Rhodococcus in the Medical Setting 
 It is already known that Rhodococci have an exceptional ability to degrade hydrophobic 
natural compounds as seen by their success in the area of fossil fuel desulfurization. This 
success can be because their large genome size and the typical appearance of large linear and 
circular plasmids allow for the presence of many catabolic enzymes and secondary metabolites 
(Ludmila et al. 2009). Rhodococci produce oxygenases, enzymes that are able to oxidize 
compounds. However, the potential of secondary metabolic compounds has not been explored 
for their use in a medical setting.  
Present Work 
In the present study we examine the cytotoxicity of polar compounds that have been 
extracted from various strains of Rhodococcus on the MCF7 breast cancer cell line. The 
cytotoxicity, or the loss of viability of a cancer cell by an external source was determined using 
an MTT assay. Based on the phylogeny of the genus Rhodococcus and its relation to other drug-
producing families in the order Actinomycetales, we hypothesize that Rhodococcus may 
produce compounds that will show activity against the MCF7 breast cancer cell line.   
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CHAPTER 2 
MATERIALS AND METHODS 
 
Bacterial Strains 
 Sixty isolated strains of Rhodococcus were used in this study. These bacterial isolates 
were cultivated from soil samples from multiple sites in Eastern Tennessee as well as several 
sites abroad (Table 3). Each strain was purified and catalogued by previous graduate students 
Tom Barber (Barber 2010) and Ralitsa Borisova (Borisova 2011).  
Table 3: Isolated bacterial strains from the genus Rhodococcus collected and purified from 
various soil samples.  
WFDE08  NPDEM14  NPDE012  CODE08  
MTDE09  WFDEM2  WLDET3  CBRMT10  
MTM306  MTM3W5.2  NP3T8.1  APDE02  
NFDEM13  KCHXC3  MTM3T17  WFDEM3 
MTM3W13  NPM311  MTM3W12.1a  CBM3T2  
CBM3W9  CBRMT7  MTM310  MTM3T5  
BTHXC2  MTM304  CODET15  EMHX01  
A2M306  BTHXC10  CBM3T2  ACM3C8  
ACM3W1  BTHXC8  DSM301 AZM3R1  
NPDE011  CODET15  WLDE08  WDM310A 
BTHXC10  WDM3P2  ACM3C1  WFIEW1  
WFDEM6  SCM3011  MTM3015  WFDEM6  
ACM3W7  MTM309a  ACM3W7  WDM318  
MTM304  MTM3T20  CBRMT7  ACM3W5  
NPM311  WDM310a  WDEW  MTDE09  
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Growth Conditions 
 All strains were grown using Rich Media (RM) broth and agar. RM was prepared using 
the following components: 
Rich Media (RM) agar 
1) Distilled H2O                               500 milliliters(mL) 
2) Dextrose                               5 grams(g) 
3) Nutrient Broth                              4 g 
4) Yeast Extract                               0.25 g 
5) Bacto Agar                                   7.5 g 
 
Rich Media (RM) broth 
1) Distilled H2O                               500 milliliters(mL) 
2) Dextrose                               5 grams(g) 
3) Nutrient Broth                              4 g 
4) Yeast Extract                               0.25 g 
 
For agar media 30ml of the autoclaved RM was poured into 100 mm petri dishes. The 
agar was allowed to cool and solidify at room temperature followed by storage at 4°C until use. 
For RM broth media 100ml of the autoclaved broth was transferred into five 150ml sterile 
bottles and stored at room temperature until use.  
 
 
26 
 
Seed Cultures and Agar Plates 
Seed cultures of each strain were prepared and used for inoculation of agar plates for 
compound extraction. A small amount of bacterial culture for each strain was taken from RM 
storage slants using a sterile loop. The bacteria were placed in a test tube containing 2.5 mL of 
RM broth. Each tube was placed in a water bath at 30°C for 24 hours or until the broth reached 
an appropriate level of turbidity to indicate bacterial growth.  
The bacteria grown in the broth was then used to inoculate the agar plates. For each 
strain 100µL of the seed culture was transferred to a 100mm diameter RM agar plate and 
spread over the entire surface of the agar using a sterile cotton swab. Each plate was then 
wrapped in parafilm to prevent desiccation and left to grow at room temperature on the 
laboratory bench top for 2-4 weeks.  
Compound Agar Extraction 
 An agar extraction method was used to collect any polar compounds that were being 
made and released by the soil isolates (derived from Carr, 2010). After growth for 2-4 weeks, 
each agar plate was divided in half. Each half was placed into a 100mL beaker and the agar was 
chopped into small pieces. Two beakers for each strain underwent extraction; one with 100% 
methanol and the other with 100% ethyl acetate. In each case 50mL of the solvent was added 
to the designated beaker with the chopped up agar and left covered for 24 hours in a fume 
hood. After soaking for 24 hours, the methanol extract and the ethyl acetate extracts were 
poured into separate 100mL labeled beakers. These beakers containing the extracts were left 
uncovered in a designated corner of the fume hood to evaporate for 24 to 72 hours. The agar 
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that remained in the first set of beakers was then treated with another 50mL of either 
methanol or ethyl acetate, covered, and left to soak for another 24 hours. After this, the 
extracts were combined with the previous extracts in their respective beakers and left for 1-4 
days in the fume hood for complete evaporation (Figure 1a). Each of the extracts was then 
redissolved in 1.5mL of 100% methanol and transferred to a 1.5mL eppendorf tube and stored 
at 4°C until use (Figure 1b).  
 
 
 
Figure 1: a. Extraction from agar cultures (adapted from Borisova 2011) b. Resuspension of 
extract in methanol and sterilization in preparation for the MTT assay.  
 
Cancer Cell Lines 
The cell lines used in these studies were MCF7, a Human Breast Adenocarcinoma (cat # 
HTB-22, ATCC, Manassas, Virginia) and LM929. The MCF7 were the experimental cell line that 
was originally harvested from the mammary gland of a 69 year old Caucasian female. The 
a.  
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LM929 cells are from a macrophage cell line and were generously donated by Stephen Chapes 
(Kansas State University, Manhattan, Kansas). The LM929 cells represent healthy tissue and 
were selected as a cellular control.  
Cell Preparation and Treatment 
 The LM929 cell line was maintained by culture in Dulbecco's Modified Eagle Medium 
(DMEM) supplemented with 10% Fetal Bovine Serum (FBS). No antibiotics were added to the 
culture media. Passage of these cells was executed using the following procedure. Cellular 
debris and used media was suctioned out of the 25cm3 culture flask (Fisher Sci, Pittsburgh, 
Pennsylvania) and 2 ml of Trypsin (1X) was added to the flask. LM929 cells are adherent cells 
and form cellular adhesions that allow them to attach to the bottom of the flask. The addition 
of Trypsin promotes the breaking of the cellular adhesions and causes release of the cells into 
the solution in order for cell harvesting and transfer. The Trypsin was left in the flask with the 
LM929 cells for 3-5 minutes while the flask remained in the sterile hood. Cells were then rinsed 
from the flask using 4 ml of DMEM supplemented with 10% FBS. The collected suspension with 
a total volume of 6 ml (cells, 2 ml Trypsin, 4 ml DMEM media) was transferred to a 15 ml 
centrifuge tube (Fisher Sci, Pittsburgh, Pennsylvania) and centrifuged (1200 rpm, 5 min, 6°C). 
After centrifugation, the supernatant was removed and disposed of. The cellular pellet was 
resuspended in 6 ml of DMEM supplemented with 10% FBS. A fraction of this suspension was 
added to the culture flask and brought up to a final volume of 6 ml with DMEM supplemented 
with 10% FBS and returned to the incubator (37°C, 5% CO2).  
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An alternate procedure was used to maintain the MCF7 cell line. DMEM supplemented 
with 10% FBS was used in the same quantities as described with the LM929 cell line. MCF7 cells 
were collected by suctioning out the media in the 25 cm3 flask and adding 2 ml of Trypsin. The 
flask was then placed in the incubator (37°C, 5% CO2) for 25-30 minutes. MCF7 cells form cell 
adhesions to the bottom of the flask and to their neighboring cells. These adhesions make the 
cells appear very clumpy and, when compared to those of the LM929 are stronger and cause 
the cell to adhere more strongly to the flask and its neighboring cells. Therefore, a longer 
incubation period with the trypsin is needed to cause the MCF7 cells to release from the 
bottom of the flask and separate from their neighboring cells. After incubation the cells in the 
flask were rinsed with 4 ml of DMEM supplemented with 10% FBS and the cell suspension 
(cells, 2 ml Trypsin, 4 ml DMEM media) collected and transferred to a 15 ml centrifuge tube 
(Fisher Sci. Pittsburgh, Pennsylvania). The tube was centrifuged at 450 rpm for 5 minutes at 6°C. 
The supernatant was then removed and the cell pellet was resuspended in 6 ml of DMEM 
supplemented with 10% FBS. A fraction of this suspension was added to the 25 cm3 culture 
flask and brought up to a final volume of 6 ml with DMEM supplemented with 10% FBS and 
returned to the incubator (37°C, 5% CO2). 
MTT Assay 
An MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay is a 
colorimetric assay that is used to examine cell viability. This assay is based on a cellular 
reduction reaction that takes place in the mitochondria of living cells (Figure 2). MTT is a 
positively charged tetrazolium salt that is a pale yellow color. It is taken up by the cell and 
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enters into the mitochondrion. Within the mitochondrion MTT is acted on by the enzyme 
mitochondrial reductase and converted to formazan, a purple colored crystal. Once the MTT is 
converted to formazan crystals, it cannot pass through or be transported across the plasma 
membrane and begins to accumulate within the cell. After a fixed incubation period, a 
solubilization buffer is added. This buffer lyses the cells and dissolves any formazan crystals that 
were formed. If there were living cells in the test wells, there would be mitochondrial reductase 
activity promoting MTT conversion to formazan crystals. In this case the addition of the 
solubilization buffer would result in the solution in the test well turning a purple color. If there 
were no living cells present in the test well, there would be no active mitochondrial reductase 
enzyme to convert MTT to formazan crystals. This would result in a test well that has no purple 
color. Absorbencies for each of the test wells are measured with a plate reader. Varying shades 
of purple color that are measured in each well are proportional to the number of living cells in 
that well. This means that lighter purple color indicates fewer living cells and dark purple color 
indicates more living cells. The MTT assay is used as a quantitative method to allow cell viability 
to be determined through a colormetric, or color changing reaction which is directly 
proportional to the activity of the mitochondrion.  
 
 
 
Figure 2: Conversion of MTT to formazan in the mitochondria (Stockert et al, 2012)   
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In preparation for the MTT assay cells were collected from a 25 cm3 flask of the 
appropriate cell line and transferred to a Corning 75 cm3 flask (Fisher Sci, Pittsburgh, 
Pennsylvania) in order to increase cell yield. These larger flasks were maintained using the same 
procedures as mentioned above corresponding to their cell line. Once the fraction of cells was 
added to the 75 cm3 flask, DMEM supplemented with 10% FBS was added to a final volume of 
15 ml. Cells were grown until confluency was achieved before an assay was performed.   
Cells from the MCF7 and LM929 cell lines were collected from confluent 75 cm3 flasks 
using the procedures mentioned above with the only modifications being the use of 5mL of 
trypsin in order to break cell adhesions and 6mL of DMEM supplemented with 10% FBS to rinse 
the flask. The incubation times and centrifugation parameters were all kept consistent for all 
flasks of each cell line. After cells were centrifuged the supernatant was removed and the cell 
pellet was resuspended with 10mL of DMEM supplemented with 10% FBS. A cell count was 
then preformed using a hemocytometer and a new cell suspension of 5 x 104 cells/mL was 
made. This new cell suspension was used to seed all the wells of the 96 well cell culture plates 
used for the MTT assay so that there were 5 x 104 cells per well.  
 Each well of the 96 well cell culture plate was seeded with 100µl of DMEM 
supplemented with 10% FBS. An additional 70µl of DMEM supplemented with 10% FBS was 
added to the first 3 wells of each of the rows corresponding to a sample. Next, 30µl of filter 
sterilized sample compounds was added to the first 3 wells of a row. The compounds were then 
serially diluted in triplicate across one row of the cell culture plate by removing 100µl from each 
of the first 3 wells and pipetting it into the following triplicate of wells in that row using a 
32 
 
multichannel pipette for accuracy. The dilution was carried out through the last triplicate of the 
row and the remaining 100µl from the last 3 wells after dilution was discarded. 100µl of the 5 x 
104 cell dilution was then added to each of the wells. The final volume of each well was 200µl 
(Figure 3). Each set of assay cell culture plates was run with a serial dilution in triplicate of HCl 
across 2 rows in order to establish a percent killing curve. Additional controls run across one 
row of wells in triplicate included cells in media only control, a 15% methanol control, a 15% 
blank methanol RM agar plate extraction control and a 15% blank ethyl actetate-methanol RM 
agar plate extraction control.  
 
Figure 3: MTT assay cell culture plate set up  
All cell culture plates were placed in the incubator (37°C, 5% CO2) for 72 hours. These 
conditions promoted cell growth and proliferation while giving the cells enough time to 
propagate so that any effect the compound had on cell growth could be observed.  After this 
incubation period, the plates were removed from the incubator and 20µl of MTT reagent was 
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added to each well. The plates were then placed back into the incubator for an additional 4 
hours to allow the MTT to be taken up by any living cells and converted to formazan crystals by 
the enzyme mitochondrial reductase. After this incubation period, the cell culture plates were 
removed from the incubator and the growth media in each well was suctioned off and 
discarded, taking care not to suction off the cells that were still adherent to the bottom of the 
wells. Then, 200µl of Iso-PBS, a solubilization buffer, was added to each of the wells in order to 
dissolve any formazan crystals that were present in the wells. Each plate was then wrapped 
tightly with plastic wrap and left overnight on the bench top at room temperature and read by 
the plate reader the following day. This was to ensure that the Iso-PBS solubilization buffer had 
sufficient time to dissolve all the formazan crystals that were formed in order to get an accurate 
absorbency reading of each test well.  
The cell culture plates were read using at plate reader at 620nm. After the plates were 
read and the absorbencies recorded, the average absorbency of each triplicate was calculated. 
The percent kill (% kill) and percent inhibition of each of the compounds and controls was 
determined by comparing the average absorbency of the sample triplicate to the average 
absorbency of each of the controls using the following formulas where Max = the acid control, 
Ctl = the media control, A = mean absorbance value of treated wells, and B = mean absorbency 
values of the control wells.   
% Kill = (Exp – Ctl)/(Max-Ctl) x 100 
% Inhibition = (1-A/B) x 100% 
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The absorbencies of each of the compounds were evaluated using a two-way ANOVA. 
Being that each treatment was done in triplicate it was important to select a test that 
considered the spread of the data within each treatment and was able to compare the means 
of each treatment. The two-way ANOVA statistical test was chosen because it is a more robust 
statistical analysis that is able to determine if there is a statistically significant difference 
between the means of the treatments relative to the spread of the observations for each 
concentration treatment.  
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CHAPTER 3 
RESULTS 
MTT Assay Analysis 
A two-way ANOVA was performed for each one of the compound extracts in order to 
assess if there was a significant variation between the mean absorbency reading at 620nm of 
the triplicates undergoing treatment and the means of the control triplicates. Each of the 
compound extracts was compared to a media control and to a methanol control that was 
conducted on the same set of assay plates in order to control for factors such as barometric 
pressure, humidity, and cell passage number. The methanol compound extracts were then 
compared to a blank-methanol control while the ethyl acetate extracts were compared to a 
blank-ethyl acetate methanol control. The hydrochloric acid control (HCl) was not used to 
compare the treatments because it demonstrated an all or nothing cell survival response and a 
cell survival curve could not be determined.   
A nonsignificant two-way ANOVA, meaning the p-value for interaction is above the level 
of significance (α > 0.05), indicates that the effect of concentration is similar for the treatment 
and the control. The interaction plot for a compound and a control that was not significant 
would show the control and the treatment with the compound extract behaving in a similar 
pattern with respect to concentration (Figure 4).  
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Figure 4: Non-significant interaction plot with LM929 cells between the media control and 
strain CODET15 meth. Both the media control and CODET15 meth show a decrease in the 
triplicate mean with an increase in concentration.  
 
A significant two-way ANOVA, meaning the p-value for interaction is below the level of 
significance (α < 0.05), indicates that the effect of concentration is different for the treatment 
and the control. The interaction plot for a compound and a control that was significant would 
show the control and the compound extract behaving differently with respect to the 
concentration (Figure 5).  
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Figure 5: Significant interaction plot with LM929 cells between the media control and strain 
MTM3015 meth. Both the media control and MTM3015 meth show a decrease in the triplicate 
mean with an increase in concentration, however MTM3015 showed a significant decrease in 
mean absorbency at the 7.5% and 15% concentrations. 
 
MCF7 MTT Assays 
 All 3 controls had a significant interaction p-values when compared to the media control 
(Figure 6). As the concentration of the control treatment increased, the absorbency decreased.  
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Figure 6: The interaction plot for MCF7 cells assayed on plates 1-5. The methanol control,  
BLANK methanol control and the BLANK EA-M controls showed a significant interaction  
(p < .05). 
  
In comparing all 60 compound extracts, as well as the methanol, blank-methanol, and 
blank ethyl acetate-methanol controls to the media control in the assays using MCF7 cells, it 
was seen that all 60 showed an interaction p-value that was significant (α < 0.05). This means 
that the addition of each of the compound extracts to their respective wells caused there to be 
a significant difference in the mean absorbency of the treated triplicates when compared to the 
mean absorbencies of the media control triplicates. In looking at the individual interaction plots 
it was seen that the biggest variation in mean absorbency reading was seen at the 15% 
concentration and the 7.5% concentration (Figure 7).  This indicates that at higher 
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concentrations of compound extract, there were fewer living cells as indicated by the low 
absorbency reading.  
 
Figure 7: The interaction plot for strain KCHXC3 with MCF7 cells showing a significant 
interaction when compared to the media and agar controls (p < .05). 
 
 
  In comparing 60 compound extracts to the methanol control, 36 of them showed an 
interaction p-value that was significant. Eighteen of these compounds extracts were methanol 
and the other 18 where ethyl acetate-methanol compound extracts (Table 4).  
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Table 4: a. Methanol compound extracts that showed significant interaction p-values 
when compared to the methanol control. b. Ethyl Acetate-Methanol compound extracts 
that showed significant interaction p-values when compared to the methanol control. 
 
          a. 
 
 
 
          b. 
  
 
 
 
 
 The blank-methanol control was used to account for any component in the agar that 
may have an effect on the proliferation of the MCF7 breast cancer cells. The blank-methanol 
rich media (RM) plates did not contain bacteria and were extracted using the same methods as 
the RM plates with bacteria. There were 11 methanol compound extracts that had a significant 
p-value when compared to the blank methanol control (Table 5).  
 
 
 
 
WLDET3 meth  AZM3R1 meth  WDM3P2 meth  
DSM301 meth ACM3W7 meth  CODET15 meth  
MTM3015 meth  NPDE011 meth ACM3W7 meth  
WFIEW1 meth  MTM309a meth  WDM310A meth 
SCM3011 meth  WDM318 meth WFDEM6 meth 
CBRMT7 meth  ACM3W5 meth WDM310a meth 
NFDEM13 EA-M MTM3W12.1a EA-M  WDM3P2 EA-M 
DSM301 EA-M  BTHXC10 EA-M  AZM3R1 EA-M  
WFDEM6 EA-M NPDE011 EA-M  ACM3W7 EA-M  
WLDE08 EA-M  MTM309a EA-M WDM310A EA-M  
ACM3W7 EA-M  WFIEW1 EA-M  WDM318 EA-M 
ACM3C1 EA-M   WFDEM6 EA-M   MTM3T20 EA-M 
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Table 5. Compounds extracts that showed a significant interaction p-value when 
compared in a two-way ANOVA to the blank-methanol control.  
WFDE08 meth NPDEM14 meth 
CODE08 meth WFDEM2 meth 
WLDET3 meth CBRMT10 meth 
MTM3W5.2 meth NFDEM13 meth 
KCHXC3 meth 1 KCHXC3 meth 2 
MTM3T17 meth 
 
 For the bacterial strains that were extracted using ethyl acetate and methanol, a blank 
ethyl acetate-methanol (EA-M) control was used.  All the strains that were extracted with ethyl 
acetate and reconstituted in methanol were compared to this control in order to assess if there 
was a component of the agar that was causing a variation in the absorbency reading or the 
variation was caused by something in the compound extract. There were 24 ethyl acetate-
methanol compounds extracts that showed significant interaction p-values when compared to 
the blank EA-M control (Table 6). 
Table 6: Compound extracts that showed significant interaction p-values when compared in a 
two-way ANOVA to the blank EA-M control.  
 
 
 All compound extracts that showed interaction with any of the controls were noted and 
used for comparison to the interaction with LM929 cells (Table 7).   
WFDE08 EA-M NPDEM14 EA-M NPDE012 EA-M CODE08 EA-M 
MTDE09 EA-M WFDEM2 EA-M WLDET3 EA-M CBRMT10 EA-M 
MTM306 EA-M MTM3W5.2 EA-M NP3T8.1 EA-M APDE02 EA-M 
NFDEM13 EA-M KCHXC3 washed EA-M KCHXC3 EA-M 1 KCHXC3 EA-M 2 
MTM3T17 EA-M BTHXC8 EA-M CODET15 EA-M WFIEW1 EA-M 
SCM3011 EA-M ACM3W7 EA-M WDM318 EA-M MTM3T20 EA-M 
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Table 7: Summary of all the extracts that showed significant interaction p-values in a two way 
ANOVA when compared to a methanol, blank methanol, and blank ethyl acetate-methanol 
control for the MTT assays conducted with MCF7 cells.  
Strain Methanol Blank 
Meth 
Blank  
EA-M 
WFDE08 meth no yes  
WFDE08 EA-M no  yes 
NPDEM14 meth no yes  
NPDEM14 EA-M no  yes 
NPDE012 EA-M no  yes 
CODE08 meth no yes  
CODE08 EA-M no  yes 
MTDE09 EA-M no  yes 
WFDEM2 meth no yes  
WFDEM2 EA-M no  yes 
WLDET3 meth yes yes  
WLDET3 EA-M no  yes 
CBRMT10 meth no yes  
CBRMT10 EA-M no  yes 
MTM306 EA-M no  yes 
MTM3W5.2 meth no yes  
MTM3W5.2 EA-M no  yes 
NP3T8.1 EA-M no  yes 
APDE02 EA-M no  yes 
NFDEM13 meth no yes  
NFDEM13 EA-M yes  yes 
KCHXC3 washed EA-M no  yes 
KCHXC3 meth 1 no yes  
KCHXC3 EA-M 1  no  yes 
KCHXC3 meth 2 no yes  
KCHXC3 EA-M 2 no  yes 
MTM3T17 meth no yes  
MTM3T17 EA-M no  yes 
MTM3W12.1a EA-M yes  no 
BTHXC8 EA-M no  yes 
DSM301 meth yes no  
DSM301 EA-M yes  no 
 
Strain Methanol  Blank 
Meth 
Blank 
EA-M 
AZM3R1 meth yes no  
AZM3R1 EA-M yes  no 
NPDE011 meth yes no  
NPDE011 EA-M yes  no 
CODET15 meth yes no  
CODET15 EA-M no  yes 
WLDE08 EA-M yes  no 
WDM310A meth yes no  
WDM310A EA-M yes  no 
BTHXC10 EA-M yes  no 
WDM3P2 meth yes no  
WDM3P2 EA-M yes  no 
ACM3C1 EA-M yes  no 
WFIEW1 meth yes no  
WFIEW1 EA-M yes  yes 
WFDEM6 meth yes no  
WFDEM6 EA-M yes  no 
SCM3011 meth yes no  
SCM3011 EA-M no  yes 
MTM3015 meth yes no  
WFDEM6 EA-M yes  no 
ACM3W7 meth yes no  
ACM3W7 EA-M yes  no 
MTM309a meth yes no  
MTM309a EA-M yes  no 
ACM3W7 meth yes no  
ACM3W7 EA-M yes  yes 
WDM318 meth yes no  
WDM318 EA-M yes  yes 
MTM3T20 EA-M yes  yes 
CBRMT7 meth yes no  
ACM3W5 meth yes no  
WDM310a meth yes no  
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LM929 MTT Assays 
 It is important to use the LM929 cell line in this investigation. This cell line acts as a 
healthy cell control. In the scope of cancer treatment, the ideal goal is to eradicate the 
cancerous cells while leaving the healthy cells unharmed. While it is important to assay for the 
effect of potential compounds against cancerous cells, it is also important that the compounds 
be assayed with healthy cells to assess their effects. A strong candidate for further investigation 
would be a compound that showed significant interaction when assayed with MCF7 cells but 
nonsignificant interaction when assayed with LM929 cells.  
 All 60 compound extracts, as well as the blank-methanol and blank-ethyl acetate-
methanol controls, were assayed using LM929 cells and compared in a two-way ANOVA to 
media and methanol controls. When compared to the media control, the methanol control did 
not show a significant interaction p-value; however, both the blank-methanol and blank EA-M 
controls did show a significant interaction p-value (Figure 8). Again a significant P-value 
indicates that that the test component in the well is behaving differently than the control to 
which it is being compared.  
 
 
 
 
44 
 
 
Figure 8: The interaction plot for LM929 cells assayed on plates 1-4. The BLANK methanol 
control and the BLANK EA-M controls showed a significant interaction while the methanol 
control did not show a significant interaction p-value.  
 
There were 16 methanol compound extracts and 21 EA-M compound extracts that 
showed significant interaction p-values in a two-way ANOVA when compared to the media 
control (Table 8).   
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a. 
b. 
Table 8: a. Methanol compound extracts that showed significant interaction p-values when 
compared to the media control in a two-way ANOVA. b. EA-M compound extracts that showed 
significant interaction p-values when compared to the media control in a two-way ANOVA.  
    
 
 
 
 
 
 
 
 
 There were 8 methanol compound extracts and 7 EA-M compound extracts that had 
significant interaction p-values against the methanol control (Table 9). 
 
 
 
 
CBRMT10 meth NP3T8.1 meth 
ACM3C8 meth ACM3W1 meth 
BTHXC2 meth MTM3010 meth 
MTM304 meth CODET15 meth 
MTM3W12.1a meth KCHXC3 washed meth 
DSM301 meth AZM3R1 meth 
MTM3015 meth WFDEM6 meth 
ACM3W7 meth MTM309a meth 
KCHXC3 EAM MTM3W12.1a EAM 
AZM306 EAM BTHXC10 EAM 
ACM3C8 EAM ACM3W1 EAM 
BTHXC8 EAM BTHXC2 EAM 
MTM3010 EAM CODET5 EAM 
EMHX01 EAM KCHXC3 EAM 2 
MTM3W13 EAM NPM311 EAM 
KCHXC3 washed EAM DSM301 EAM 
AZM3R1 EAM NPDE011 EAM 
MTM3015 EAM MTM309a EAM  
MTM304 EAM  
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a. 
b. 
Table 9: a. Methanol compound extracts that showed significant interaction p-values 
when compared with a methanol control in a two-way ANOVA. b. EA-M compound 
extracts  that showed significant interaction p-values when compared with a methanol 
control in a two-way ANOVA.  
 
 
 
 
 
  
 A blank-methanol control was used in the two-way ANOVA analysis for those compound 
extracts that were extracted with methanol. There were 23 methanol compound extracts that 
showed significant interaction p-value (Table 10a). A blank EA-M control was used in the two-
way ANOVA analysis for those compound extracts that were extracted with ethyl acetate and 
reconstituted in methanol. There were 23 EA-M compound extracts that showed significant 
interaction p-values (Table 10b). 
 
 
 
 
 
CBRMT10 meth ACM3C8 meth 
MTM3010 meth MTM304 meth 
CODET15 meth MTM3T17 meth 
MTM3W12.1a meth KCHXC3 washed meth 
NFDEM13 EAM KCHXC3 EAM 
AZM306 EAM BTHXC2 EAM 
MTM3010 EAM EMHX01 EAM 
KCHXC3 washed EAM  
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Table 10: a. Methanol compound extracts that showed significant interaction p-values when 
compared to a blank methanol control. b. Ethyl acetate-methanol compound extracts that 
showed significant interaction p-values when compared to a blank EA-M control.  
a.  
 
 
 b. 
 
 
 
 
 
 A summary of all the compound extracts and their activity with LM929 cells were noted 
to be used for a comparison (Table 11).  
 
 
 
 
 
 
 
 
 
 
WFDE08 meth NPDEM14 meth MTDE09 meth 
WFDEM2 meth MTM306 meth MTM3W5.2 meth 
MTM3W12.1 a meth ACM3C8 meth MTM310 meth 
MTM3010 meth CODET15 meth MTM3T17 meth 
KCHXC3 washed meth KCHXC3 meth 1 CODET15 meth 
WLDE08 meth ACM3C1 meth WFIEW1 meth 
SCM3011 meth ACM3W7 meth NPM311 meth 
WDM310a meth MTDDE09 meth   
WFDE08 EAM MTDE09 EAM MTM306 EAM 
NFDEM13 EAM KCHXC3 EAM AZM306 EAM 
CBM3T2 EAM  CBMT7 EAM  MTM310 EAM 
BTHXC2 EAM MTM3010 EAM KCHXC3 EAM 2 
NPM311 EAM KCHXC3 washed EAM KCHXC3 EA- 1 
CODET15 EAM WLDE08 EAM WDM3P2 EAM 
ACM3C1 EAM WFDEM6 EAM SCM3011 EAM 
ACM3W7 EAM WDM318 EAM   
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Table 11: Summary of all the extracts that showed significant interaction p-values in a two-way 
ANOVA when compared to a media, methanol, blank methanol, and blank ethyl acetate-
methanol control for the MTT assays conducted with LM929 cells. 
Strain Media Methanol Blank 
Meth 
Blank 
EA-M  
WFDE08 meth no no yes  
WFDE08 EA-M no no  yes 
NPDEM14 meth no no yes  
MTDE09 meth no no yes  
MTDE09 EA-M no no  yes 
WFDEM2 meth no no yes  
CBRMT10 meth yes yes no  
MTM306 meth no no yes  
MTM306 EA-M no no  yes 
MTM3W5.2 
meth 
no no yes  
NP3T8.1 meth yes no no  
NFDEM13 EA-M no yes  yes 
KCHXC3 EA-M yes yes  yes 
MTM3W12.1 a 
meth 
no no yes  
MTM3W12.1a 
EA-M 
yes no  no 
AZM306 EA-M yes yes  yes 
BTHXC10 EA-M yes no  no 
CBM3T2 EA-M  no no  yes 
ACM3C8 meth yes yes yes  
ACM3C8 EA-M yes no  no 
ACM3W1 meth yes no no  
ACM3W1 EA-M yes no  no 
BTHXC8 EA-M yes no  no 
CBMT7 EA-M  no no  yes 
MTM310 meth no no yes  
MTM310 EA-M no no  yes 
BTHXC2 meth yes no no  
BTHXC2 EA-M yes yes  yes 
MTM3010 meth yes yes yes  
MTM3010 EA-M yes yes  yes 
MTM304 meth yes no no  
CODET15 meth yes yes yes  
CODET5 EA-M yes no  no 
EMHX01 EA-M yes yes  no 
KCHXC3 EA-M 2 yes no  yes 
MTM3T17 meth no yes yes  
MTM3W13 EA-
M 
yes no  no 
Strain Media Methanol Blank 
Meth  
Blank 
EA-M 
NPM311 EA-M yes no  yes 
MTM3W12.1a 
meth 
yes yes yes  
KCHXC3 washed 
meth 
yes yes yes  
KCHXC3 washed 
EA-M 
yes yes  yes 
KCHXC3 meth 1 no no yes  
KCHXC3 EA-M 1 no no  yes 
DSM301 meth yes no no  
DSM301 EA-M yes no  no 
AZM3R1 meth yes no no  
AZM3R1 EA-M yes no  no 
NPDE011 EA-M yes no  no 
CODET15 meth no no yes  
CODET15 EA-M no no  yes 
WLDE08 meth no no yes  
WLDE08 EA-M no no  yes 
WDM3P2 EA-M no no  yes 
ACM3C1 meth no no yes  
ACM3C1 EA-M no no  yes 
WFIEW1 meth no no yes  
WFDEM6 EA-M no no  yes 
SCM3011 meth no no yes  
SCM3011 EA-M no no  yes 
MTM3015 meth yes no no  
MTM3015 EA-M yes no  no 
WFDEM6 meth yes no no  
ACM3W7 meth yes no no  
MTM309a meth yes no no  
MTM309a EA-M  yes no  no 
ACM3W7 meth no no yes  
ACM3W7 EA-M no no  yes 
WDM318 EA-M  no no  yes 
MTM304 EA-M yes no  no 
NPM311 meth no no yes  
WDM310a 
meth 
no no yes  
WDEW3 meth no no no  
MTDDE09 meth  no no yes  
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Activity Comparison in the MCF7 and LM929 Cell Lines 
 An ideal candidate for further investigation would be a compound extract that showed 
growth inhibition or killing activity when assayed with the MCF7 cells but no activity when 
assayed with the LM929 cells. Evaluation based on the compound extract activity when 
compared to either the blank methanol or blank ethyl acetate-methanol control is used to 
evaluate potential strains of Rhodococcus that warrant further evaluation as to their compound 
properties in the cancer treatment setting. These both are reliable controls because they have 
been subject to the extraction procedure and they allow the bacterial strain compounds to be 
an isolated variable for testing.  
Among the 60 Rhodococcus strains that were assayed and the 120 compound extracts, 
18 compound extracts showed significant interaction p-values when compared to either the 
blank methanol control or the blank ethyl acetate-methanol control in the MTT assay with 
MCF7 cells (Table 12). These same compound extracts showed nonsignificant interaction p-
values when compared to the blank methanol and blank ethyl acetate-methanol controls in the 
MTT assay with LM929 cells.  
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Table 12: All of the compound extracts that showed significant interaction p-values in a 
two-way ANOVA against the blank methanol or blank ethyl acetate methanol controls in a 
MCF7 MTT assay but showed no significant interaction p-values in a two-way ANOVA against 
these same controls in a LM929 MTT assay.  
 
NPDEM14 EA-M NPDE012 EA-M 
CODE08 meth CODE08 EA-M 
WFDEM2 EA-M WLDET3 meth 
WLDET3 EA-M CBRMT10 meth 
CBRMT10 EA-M MTM3W5.2 EA-M 
NP3T8.1 EA-M APDE02 EA-M 
NFDEM13 meth KCHXC3 meth 2 
MTM3T17 EA-M BTHXC8 EA-M 
WFIEw1 EA-M MTM3T20 EA-M 
 
Washed RM Agar Plates and Their Effect on Activity 
 Washed rich media (RM) agar plates refers to removing the growing bacteria from the 
surface of the plate before extraction. Removal of the bacteria leaves only the compounds that 
were released in the agar to be extracted.  This was done with the KCHXC3 Rhodococcus strain 
in order to see if there was a difference in the activity of the compound extract when the 
bacteria were extracted along with the agar and when the agar was extracted alone.  
 Methanol compound extracts were compared for the MCF7 and LM929 MTT assays 
using a two-way ANOVA (Table 12). The strain KCHXC3 was extracted on 2 different days in 
order to observe if there was a consistency in the activity of the compound extract.  In looking 
at the MCF7 MTT assay results, it is seen that there is consistency with the activity of both the 
KCHXC3 methanol 1 and KCHXC3 methanol 2 compound extracts with both of them showing a 
significant interaction p-value when compared to the media and blank methanol controls but 
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no significant interaction when compared to the methanol control (Table 13a). When 
comparing this to the activity of KCHXC3 washed methanol compound extract there was a 
difference in activity when looking at the blank methanol control. This result could indicate that 
there is something being produced and not excreted by the bacteria that causes an inhibitory 
growth effect.  
 In the MTT assays with the LM929 cells, there was a difference in activity among the 2 
KCHXC3 compound extracts (Table 13b). The difference is with their activity when compared to 
the blank methanol control. The KCHXC3 methanol 1 compound extract showed a significant 
interaction p-value when compared to the blank methanol control while the KCHXC3 methanol 
2 compound extract did not show a significant p-value. The activity of the KCHXC3 washed 
methanol compound extract was different from both of the controls and showed a significant 
interaction p-value when compared to each one of the controls.  
 
Table 13: a. Methanol compound extracts and their activity in a MTT assay with MCF7 against a 
media, methanol, and blank methanol control separately. b. Methanol compound extracts and 
their activity in a MTT assay with LM929 cells against a media, methanol, and blank methanol 
control. A yes result indicates that the compound extract had a significant interaction p-value 
when compared to the control individually.  
 
                                                   
a. MCF7 MTT Assay Activity                                                b.   LM929 MTT Activity 
 
 
Strain Media Methanol Blank Meth 
KCHXC3 
washed meth 
yes yes yes 
KCHXC3 meth 
1 
no no yes 
KCHXC3 meth 
2 
no no no 
Strain Media Methanol Blank Meth 
KCHXC3 
washed 
meth 
yes no no 
KCHXC3 
meth 1 
yes no yes 
KCHXC3 
meth 2 
yes no yes 
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 The ethyl acetate-methanol compound extracts for the strain KCHXC3 were also 
compared. With the MCF7 MTT assay, both the KCHXC3 compound extracts showed the same 
activity with significant interact p-values compared to the media and blank EA-M controls. The 
KCHXC3 washed EA-M compound extract also demonstrated the same activity pattern with 
significant interaction p-values compared to the media and blank methanol controls and no 
significance when compared to the methanol control (Table 14a).  
 There was a difference of activity in the 2 KCHXC3 compound extracts against the 
LM929 cells. The difference is with the media control. KCHXC3 EA-M 1 compound extract did 
not show a significant interaction p-value when compared to the media control while KCHXC3 
EA-M 2 compound extract did show a significant interaction p-value (Table 14b). Both of the 
KCHXC3 EA-M compound extracts showed a different activity pattern when compared to the 
KCHXC3 washed EA-M extract. In this case the washed extracted showed a significant p-value 
when compared to all 3 controls. 
Table 14: a. Ethyl acetate-methanol compound extracts and their activity in a MTT assay with 
LM929 against a media, methanol, and blank methanol control separately. b. Ethyl acetate-
methanol compound extracts and their activity in a MTT assay with LM929 cells against a 
media, methanol, and blank methanol control. A yes result indicates that the compound extract 
had a significant interaction p-value when compared to the control individually.             
 
Strain Media Methanol Blank EA-M 
KCHXC3 
washed 
EA-M 
yes no yes 
KCHXC3 
EA-M 1 
yes  no yes 
KCHXC3 
EA-M 2 
yes no yes 
Strain Media Methanol Blank EA-M 
KCHXC3 
washed  
EA-M 
yes yes yes 
KCHXC3  
EA-M 1 
no no yes 
KCHXC3 
EA-M 2 
yes no yes 
a. MCF7 MTT Assay Activity                                    b. LM929 MTT Assay Activity  
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Extraction Using a Minimal Media 
For the MTT assays conducted with MCF7 cells, the blank methanol and blank EA-M 
extraction showed significant interaction p-values when compared to the media control in both 
the MTT assays with MCF7 and LM929 cells. These blank controls go through the same 
extraction process with the only difference being that they are not seeded with bacteria. This 
result indicates that there could be some component of the RM agar that is causing there to be 
an effect on the cells. Fiss minimal agar was used to assess if there was a component in the agar 
that was causing the activity with the MCF7 and LM929 cells in the MTT assays. Minimal media 
contains the essential components for bacteria to grow. Two separate Fiss agar plates from the 
same batch of media were extracted in order to test the activity against the 3 controls and the 
consistency of the activity. It was seen that there was no consistency in the pattern of activity 
to the controls with either the blank Fiss methanol or blank Fiss EA-M compound extracts 
(Table 15). In looking at the Blank Fiss methanol plates 1 and 2, it is seen that against the media 
control and the blank methanol control,  plate 1 showed significance and plate 2 did not.  An 
inconsistency in activity was also seen in the Blank Fiss ethyl acetate-methanol plates 1 and 2. 
In this case, plate 1 did not show significance against the media and Blank ethyl acetate-
methanol control while plate 2 did show significance against these controls.   
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Table 15: MTT assay activity results based on a two-way ANOVA against a 
media, methanol, blank methanol, and blank EA-M controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Strain Media Methanol Blank meth Blank EA-M 
Blank Fiss 
meth 1 
yes no yes n/a 
Blank Fiss 
meth 2 
no no no n/a 
Blank Fiss 
EA-M 1 
no no n/a No 
Blank Fiss 
EA-M 2 
yes no n/a yes 
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CHAPTER 4 
DISCUSSION 
 The bacterium Rhodococcus is best known for its industrial success in the area of fossil 
fuel desulfurization. Following the sequencing of its genome in 2006, it was found that it 
contains 7 polyketide synthases and 24 nonribosomal peptide synthases (McLeod et al. 2006). 
The presence of these enzymes and the knowledge that they have been shown to produce 
antibiotics in other closely related bacteria has sparked interest in exploring Rhodococcus as a 
producer of inhibitory compounds. 
Other related bacteria in the order Actinomycetales have produced compounds that 
have been used, or have influenced synthetic compounds that have been used in cancer 
treatment. Currently 9 genera in the order Actinomycetales have been studied and proved 
successful in producing drug-like products. The distribution of identified drug producing families 
on the bacterial phylogenetic tree suggest that the drug producing families tend to cluster. The 
family Nocardiaceae, which includes Rhodococcus, is related to the drug productive family 
Corynebacteriaceae that emerged in 2000 as a bioprospecting target (Zhu et al. 2011). 
Investigation into other related bacterial families could potentially lead to the discovery of 
useful bioactive compounds.  
Based on these initial findings and previous success in this lab concerning the discovery 
of compounds that show effective bacterial growth inhibition, we hypothesized that 
Rhodococcus would be a bioprospecting target for inhibitory compounds against MCF7 breast 
cancer cells. Upon agar extraction screening using methanol and ethyl acetate, 18 compound 
extracts from 15 strains of Rhodococcus have shown significant activity against MCF7 breast 
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cancer cells while demonstrating no significant activity against the healthy cell control line of 
LM929 cells.  
The results of this initial screening of these strains of Rhodococcus show promise in 
further investigation of this genus; however, a more in-depth investigation is necessary to 
determine the widespread potential of these compounds in the cancer treatment setting. It was 
seen that the blank methanol and blank ethyl acetate-methanol controls show significance 
when compared to the media control in both the MTT assays with MCF7 cells and LM929 cells. 
This indicates that there could be some component in the rich media agar that is causing this 
response. When the fIss media agar was tested, it was seen that each 1 of the 2 fiss agar 
extracts showed a different activity pattern. Further testing with this agar is suggested to 
confirm activity. If it shows no significant activity when compared to the media control, it would 
be a good candidate to grow and extract bacteria. If this is not the case, the use of another agar 
or agarose that does not have an effect on the growth of the cells would be an ideal choice.  
Another possibility for growth media is nutrient broth. Allowing the bacteria to grow in 
liquid media with porous resin instead of on a solid surface could cause the production of these 
effective compounds. Changing from a solid surface to a liquid media form does have the 
potential to change bacteria expression and the compounds that the bacteria produce. This 
change in expression may be due to quorum sensing, a signaling system in bacteria that 
coordinates gene expression based on cell density (Martin et al. 2005).  Changing to broth 
media could alter the identified activity of the compound extracts and may be a productive 
avenue for further bioactive compound production.  
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In looking at the dispersion of bioactive compounds there is an imbalance of distribution 
among the sets of assay plates. Out of the 5 sets of assay plates conducted for the MTT assays 
with MCF7 breast cancer cells, the majority of the significant compound extracts were found in 
the first set of plates. Because each of the compound extracts is compared to the 3 controls 
that are run on that set of plates it could be that there was an inaccuracy in the controls on the 
first set of plates. This would explain almost all of the compounds showing significant 
interaction p-values when compared to the blank methanol and blank ethyl acetate-methanol 
control. These compounds would need to be run again dispersed on different assay plates to 
confirm the positive activity.  
The hypothesis for this investigation was that compound extracts from various strains of 
Rhodococcus would have some type of activity when grown with MCF7 breast cancer cells. 
More specifically we hypothesized that based on previous bioactivity discovered within the 
related bacterial families and the production of growth inhibiting compounds against bacteria 
from Rhodococcus strains isolated in the lab, there would be some compound or combination 
of compounds produced by this genus of bacteria that would have a inhibitory growth effect or 
killing effect on MCF7 breast cancer cells. Eighteen compounds that showed significant 
interaction p-values when assayed with the MCF7 breast cancer cells were identified. These 
compounds were also selected for future prospecting research because they showed a lack of 
activity against the LM929 healthy cell line. In this investigation we reject our null hypothesis 
that a compound produced by Rhodococcus does not cause an effect against MCF7 breast 
cancer cells.  
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Future Direction of This Research 
  The 18 compound extracts that showed significant interaction (p < 0.05) when assayed 
with MCF7 cells and nonsignificant interaction p-values when assayed with LM929 cells require 
further investigation. The 15 strains of Rhodococcus that have shown activity represent 
potential leads for bioactivity. Purification and identification of the composition of these 
identified compound extracts could provide information about the type of compound or 
combination of compounds that are having an effect on the MCF7 cancer cells. Further 
expansion of these strains of bacteria that show activity can be done with the use of other 
growth media and cancer cell lines to see if they have an inhibitory or killing effect.  
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